UCHL5 and Miyoshi myopathy: The importance of such toxicity considerations is exemplified by USP14 and UCHL5, two proteasome‐associated DUBs, whose inhibition demonstrated promising preclinical evidence to overcome bortezomib resistance in MM (Tian et al, 2014).